"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
- L Dopa
- 3 Hydroxy L tyrosine
- L 3,4 Dihydroxyphenylalanine
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
Fischer DL, Auinger P, Goudreau JL, Cole-Strauss A, Kieburtz K, Elm JJ, Hacker ML, Charles PD, Lipton JW, Pickut BA, Sortwell CE. BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
Sheshadri V, Rowland NC, Mehta J, Englesakis M, Manninen P, Venkatraghavan L. Comparison of General and Local Anesthesia for Deep Brain Stimulator Insertion: A Systematic Review. Can J Neurol Sci. 2017 11; 44(6):697-704.
Lovera LC, Rodriguez-Porcel F, Urrea-Mendoza E, Fasano A, Espay AJ. Flamenco dancer posture: Unique "off" complication in Parkinson disease. Neurology. 2016 04 12; 86(15):1462-1463.
García CR, Angelé-Martínez C, Wilkes JA, Wang HC, Battin EE, Brumaghim JL. Prevention of iron- and copper-mediated DNA damage by catecholamine and amino acid neurotransmitters, L-DOPA, and curcumin: metal binding as a general antioxidant mechanism. Dalton Trans. 2012 Jun 07; 41(21):6458-67.
Roca M, Torralva T, Gleichgerrcht E, Chade A, Arévalo GG, Gershanik O, Manes F. Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cogn Behav Neurol. 2010 Sep; 23(3):152-8.
Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990 Feb; 147(2):217-20.
Flurkey K, Randall PK, Sinha YN, Ermini M, Finch CE. Transient shortening of estrous cycles in aging C57BL/6J mice: effects of spontaneous pseudopregnancy, progesterone, L-dihydroxyphenylalanine, and hydergine. Biol Reprod. 1987 May; 36(4):949-59.
Turner SM, Beidel DC, Nathan RS. Biological factors in obsessive-compulsive disorders. Psychol Bull. 1985 May; 97(3):430-50.
Thiers BH. Chemotherapy of malignant melanoma. J Am Acad Dermatol. 1982 Mar; 6(3):412-6.